Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.
Journal: Research square
Published: July 03, 2026
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
Journal: Future oncology (London, England)
Published: April 06, 2026
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.
Journal: Journal for immunotherapy of cancer
Published: October 07, 2025
Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.
Journal: Cancer cell
Published: July 19, 2025
Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.
Journal: Cancers
Published: April 28, 2025
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.
Journal: Cancers
Published: April 13, 2025
ICTIS: A Novel Scoring System to Assess the Inclusivity of Advanced NSCLC Immunotherapy Trials.
Journal: JTO clinical and research reports
Published: March 08, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2024
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: November 27, 2024
Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis.
Journal: Cancer research communications
Published: February 20, 2024
Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications.
Journal: Frontiers in oncology
Published: December 30, 2023
The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challenges.
Journal: Journal of thoracic disease
Published: April 01, 2022
Last Updated: 09/26/2026